Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Immorna Raises $100 Million for Clinical Trials of Novel RNA Candidates

publication date: Mar 1, 2023

Immorna, a Hangzhou company developing novel RNA therapeutic and vaccine candidates, raised $100 million in a Series A+/A++ funding to support clinical development of its portfolio. Founded in 2019, the company has built multiple RNA platforms for conventional, self-replicating and circular RNA technologies. With its advanced screening tools, Immorna has developed several RNA delivery vehicles. Immorna has a total of 11 RNA candidates that target indications in cancer immunotherapy, infectious diseases, rare genetic diseases and cosmology. The company has approval to start three clinical trials for two assets in the US. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China